QUANTIFICATION OF HEPATITIS B AND HEPATITIS C VIRAL LOAD BY REAL-TIME PCR AND ASSESSMENT OF COINFECTION OF HBV AND HCV AMONG HIV-POSITIVE PATIENTS IN A TERTIARY CARE HOSPITAL

International Journal of Current Pharmaceutical Research Pub Date : 2024-03-15 DOI:10.22159/ijcpr.2024v16i2.4027

Annepu Prasanthi, Aruna Bula, Puvvula Kamala

{"title":"QUANTIFICATION OF HEPATITIS B AND HEPATITIS C VIRAL LOAD BY REAL-TIME PCR AND ASSESSMENT OF COINFECTION OF HBV AND HCV AMONG HIV-POSITIVE PATIENTS IN A TERTIARY CARE HOSPITAL","authors":"Annepu Prasanthi, Aruna Bula, Puvvula Kamala","doi":"10.22159/ijcpr.2024v16i2.4027","DOIUrl":null,"url":null,"abstract":"bjective: To assess the prevalence of coinfection of HIV-HBV and HIV-HCV and to estimate the viral load of HBV and HCV in PLWH. \nMethods: A retrospective study was conducted from November 2021 to October 2022 among patients attending ICTC. 5 ml of blood sample collected aseptically was tested for HIV, HBV and HCV using rapid immunochromatographic tests, ELISA and viral load estimated by Real-time PCR. \nResults: Out of 5087 samples tested for HIV, 666 samples (13.09%) were found to be positive. Prevalence of HIV-HBV and HIV-HCV coinfection was 15.6%(104 cases) and 1.5% (10 cases), respectively. Out of which, males were predominant (62.28%). This is clinically significant with a p-value of * 0.05. HIV-HBV and HIV-HCV coinfections were predominant in 41-50 y age group. Among104 HIV-HBV coinfected, viral load at the time of diagnosis is ‘below detection level’ in 25(24.04%), <250 in 15(14.42%), 251-500 in 9(8.65 %), 501-1000 in 13(12.5 %), 1001-10,000 in 23(22 %) and>10, 000 copies/ml in 19(18.26%). In 10 HIV-HCV coinfected cases, the viral load is ‘below detection level’ in 2(20%), <250 in 1(10%), 251-500 in 1(10 %), 501-1000 in 1(10 %), 1001-10,000 in 4(40%) and>10,001-100,000 copies/ml in 1(10%). \nConclusion: Monitoring the viral load in HBV or HCV infected at the time of diagnosis of HIV or testing for protective levels of antibodies post-vaccination in uninfected people will help in limiting the progression of chronic HBV or HCV to cirrhosis, end-stage liver disease or hepatocellular carcinoma.","PeriodicalId":13875,"journal":{"name":"International Journal of Current Pharmaceutical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Current Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ijcpr.2024v16i2.4027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

bjective: To assess the prevalence of coinfection of HIV-HBV and HIV-HCV and to estimate the viral load of HBV and HCV in PLWH. Methods: A retrospective study was conducted from November 2021 to October 2022 among patients attending ICTC. 5 ml of blood sample collected aseptically was tested for HIV, HBV and HCV using rapid immunochromatographic tests, ELISA and viral load estimated by Real-time PCR. Results: Out of 5087 samples tested for HIV, 666 samples (13.09%) were found to be positive. Prevalence of HIV-HBV and HIV-HCV coinfection was 15.6%(104 cases) and 1.5% (10 cases), respectively. Out of which, males were predominant (62.28%). This is clinically significant with a p-value of * 0.05. HIV-HBV and HIV-HCV coinfections were predominant in 41-50 y age group. Among104 HIV-HBV coinfected, viral load at the time of diagnosis is ‘below detection level’ in 25(24.04%), <250 in 15(14.42%), 251-500 in 9(8.65 %), 501-1000 in 13(12.5 %), 1001-10,000 in 23(22 %) and>10, 000 copies/ml in 19(18.26%). In 10 HIV-HCV coinfected cases, the viral load is ‘below detection level’ in 2(20%), <250 in 1(10%), 251-500 in 1(10 %), 501-1000 in 1(10 %), 1001-10,000 in 4(40%) and>10,001-100,000 copies/ml in 1(10%). Conclusion: Monitoring the viral load in HBV or HCV infected at the time of diagnosis of HIV or testing for protective levels of antibodies post-vaccination in uninfected people will help in limiting the progression of chronic HBV or HCV to cirrhosis, end-stage liver disease or hepatocellular carcinoma.

查看原文本刊更多论文

通过实时 PCR 对乙型肝炎和丙型肝炎病毒载量进行定量，并评估一家三级护理医院中 HIV 阳性患者同时感染乙型肝炎病毒和丙型肝炎病毒的情况

目标：评估艾滋病毒-HBV 和艾滋病毒-HCV 合并感染的流行率，并估计 PLWH 中 HBV 和 HCV 的病毒载量。方法：从 2012 年 1 月 1 日起开展一项回顾性研究：在 2021 年 11 月至 2022 年 10 月期间，对前往 ICTC 就诊的患者进行了一项回顾性研究。采用快速免疫层析检测法和酶联免疫吸附法对无菌采集的 5 毫升血液样本进行艾滋病毒、乙肝病毒和丙肝病毒检测，并通过实时 PCR 估算病毒载量。结果：在 5087 份艾滋病毒检测样本中，发现 666 份样本（13.09%）呈阳性。HIV-HBV 和 HIV-HCV 合并感染率分别为 15.6%（104 例）和 1.5%（10 例）。其中男性居多（62.28%）。这具有重要的临床意义，P 值为 * 0.05。艾滋病毒-乙型肝炎病毒（HIV-HBV）和艾滋病毒-丙型肝炎病毒（HIV-HCV）合并感染主要发生在 41-50 岁年龄组。在104名HIV-HBV合并感染者中，25人（24.04%）在确诊时病毒载量 "低于检测水平"，19人（18.26%）的病毒载量为10,000拷贝/毫升。在 10 例艾滋病毒-HCV 合并感染病例中，2 例（20%）的病毒载量 "低于检测水平"，1 例（10%）的病毒载量为 10,001-100,000 copies/ml。结论在诊断 HIV 时监测 HBV 或 HCV 感染者的病毒载量，或在未感染者接种疫苗后检测保护性抗体水平，将有助于限制慢性 HBV 或 HCV 向肝硬化、终末期肝病或肝细胞癌发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Current Pharmaceutical Research

自引率

0.00%

发文量